藥明生物(02269.HK)重申沒有人類基因組學業務 亦未收集人類基因組數據
藥明生物(02269.HK)就股價及成交量不尋常波動聲明,重申首席執行官及執行董事陳智勝博士既沒有為軍事醫學科學院或任何具有軍事背景的機構工作過,也沒有直接或間接從任何具有軍事背景的機構中獲得過任何報酬。此外,公司既沒有人類基因組學業務,亦未在其各類業務中收集人類基因組數據。
同時,澄清限制美國行政機關與若干生物技術供應商訂立合約的法案草案目前仍然處於較早期階段,仍有待美國立法機構進一步審議變更,尚未頒佈生效。
該股上交易日(2日)收報16.78元,下跌4.37元,跌幅20.66%;成交2.45億股,成交額43.61億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.